GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced participation in three upcoming scientific conferences.
- Cell & Gene Meeting on the Mesa — La Jolla, Calif. (October 5-7, 2016)
Sue Washer, AGTC President and CEO, will be delivering a company presentation on October 5, 2016 at 2:45 p.m. PDT and will also participate in a panel discussion titled “Gene Therapy: Commercializing a Therapeutic Product” on October 6, 2016 at 3:15 p.m. PDT.
- BioFlorida Annual Conference— Jacksonville, Fla. (October 9-11, 2016)
Sue Washer will take part in a discussion titled “Florida Areas of Strength: Cell Therapy and Regenerative Medicine” at 11:40 a.m. EDT and will be moderating the conference’s CEO Panel at 4:55 p.m. EDT on October 10, 2016.
- OIS@AAO — Chicago, Ill. (October 13, 2016)
Sue Washer will participate in the Gene & Stem Cell Therapies Breakfast Breakout Session beginning at 7:30 a.m. CDT. She will present a brief corporate overview at 11:07 a.m. CDT as part of the conference’s Posterior Segment Company Showcase.
About AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products.